Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)

Sung Hoon Jung, Je Jung Lee, Won Seog Kim, Won Sik Lee, Young Rok Do, Sung Yong Oh, Min Kyoung Kim, Yeung Chul Mun, Ho Jin Shin, Jae Yong Kwak, Hye Jin Kang, Jong Ho Won, Jung Hye Kwon, Eunkyung Park, Cheolwon Suh, Deok Hwan Yang

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

This study aimed to determine the objective response, toxicity, and clinical outcome of weekly rituximab consolidation after four cycles of R-CHOP21 in very elderly patients with DLBCL. A prospective, multi-institutional phase II trial was conducted on patients with previously untreated CD20+ DLBCL who were older than 70 yr. Patients were treated with four cycles of R-CHOP21 followed by weekly consolidation with rituximab (375mg/m2, four times infusion) (NCT01181999). We also compared the clinical outcomes with an historical case-matched control group treated conventionally with six cycles of R-CHOP21. A total of 51 patients with newly diagnosed DLBCL were enrolled at 15 institutes between June 2010 and September 2013. The median age was 76 yr (range: 70-89). Forty-one of the 51 patients completed the planned rituximab consolidation (R-consolidation). The overall response rate was 78.4%, comprising 74.5% with a complete response and 3.9% with a partial response. After a median follow-up of 20.3 months, 2-yr progression-free survival and overall survival were 63.9% and 68.7%, respectively. No serious toxicities were reported during rituximab consolidation. Weekly rituximab consolidation following four cycles of R-CHOP21 resulted in an acceptable response with high tolerability and could be a good compromise between efficacy and safety for elderly patients with DLBCL.

Original languageEnglish
Pages (from-to)504-510
Number of pages7
JournalEuropean Journal of Haematology
Volume94
Issue number6
DOIs
StatePublished - 1 Jun 2015

Keywords

  • Diffuse large B-cell lymphoma
  • Elderly
  • Rituximab consolidation

Fingerprint

Dive into the research topics of 'Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)'. Together they form a unique fingerprint.

Cite this